We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 546

Physicians urge FDA to allow distinctive names for biosimilars
  • Shook Hardy & Bacon LLP
  • USA
  • August 21 2014

A coalition of organizations representing specialist physicians and individual physicians have authored a letter to U.S. Food and Drug Administration


Guilty plea entered in cancer-drug smuggling operation
  • Shook Hardy & Bacon LLP
  • USA
  • August 21 2014

The owner of an Istanbul, Turkey-based pharmaceutical company has pleaded guilty in a Missouri federal court to charges that he shipped illegal


Mexican health-care market estimated to gain 6.8 percent compounded annually
  • Shook Hardy & Bacon LLP
  • Mexico, USA
  • August 21 2014

Research and consulting firm GlobalData reports that Mexico's health-care market, including both the pharmaceutical and medical device sectors, will


USPTO Director addresses IP issues during Advisory Committee meeting
  • Shook Hardy & Bacon LLP
  • USA
  • August 21 2014

In her opening remarks during the Patent Public Advisory Committee's August 14, 2014, meeting, U.S. Patent and Trademark Office (USPTO) Deputy


Government funding to support development of Ebola treatment
  • Shook Hardy & Bacon LLP
  • USA
  • August 21 2014

The U.S. National Institute of Allergy and Infectious Diseases has reportedly exercised options to conduct Phase 1 human-safety trials and non-human


Hearing on OTC drug review scheduled
  • Shook Hardy & Bacon LLP
  • USA
  • February 27 2014

The U.S. Food and Drug Administration (FDA) will conduct a public hearing on March 25-26, 2014, in silver spring, Maryland, "to obtain information


FDA orders 23andme to stop selling DNA tests
  • Shook Hardy & Bacon LLP
  • USA
  • December 12 2013

The U.S. Food and Drug Administration (FDA) issued a warning letter in late November 2013 to 23andMe, Inc., the company that marketed a home "Saliva


European markets less than enthusiastic over biosimilars
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • December 12 2013

While Europe has had a regulatory approval pathway for biosimilar drug products for some years, their use reportedly remains anemic. Physicians are


Tech interests praise USPTO director nomination
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

According to a news source, technology industry interests have lauded President Barack Obama's (D) choice for U.S. Patent and Trademark Office


Biotech boards dominated by men
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

A Liftstream analysis reportedly shows that the average Board of Directors in the biotechnology sphere is roughly 90 percent male and more than half